NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

Dotinurad 4 mg/d is more effective in reducing serum urate levels than febuxostat 40 mg/d at week 24 in patients with gout, a ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...